Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Otsuka Pharmaceutical Co., Ltd.

JAMA Psychiatry Publishes Results of Otsuka and Lundbeck's Phase 3 Trial of Brexpiprazole in Combination with Sertraline in Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
New Report Reveals U.S. Family Caregivers Perform Equivalent of a Staggering $873.5 Billion Worth of Labor, Would Surpass Revenue of Top Global Companies
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
Otsuka Announces Positive Interim Results from the Phase 3 Trial of Sibeprenlimab for the Treatment of Immunoglobulin A Nephropathy in Adults
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
Barbara Corcoran Announces Collaboration with Otsuka and Lundbeck to Raise Awareness of Agitation in Alzheimer’s Dementia
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
Otsuka and Lundbeck Present New REXULTI® (brexpiprazole) Post Hoc Efficacy Data Analyses for Agitation Associated with Dementia Due to Alzheimer’s Disease at Alzheimer’s Association International Conference (AAIC) 2024
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
Otsuka and Lundbeck Present Results from Three Clinical Trials of Brexpiprazole in Combination with Sertraline for the Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
Otsuka to Terminate Development of AVP-786
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
Otsuka Announces Interim Data from Phase 2b/c Trial Indicating New Investigational Compound May Shorten Tuberculosis Treatment
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
Otsuka and Lundbeck Present New Data Analyses on the Efficacy of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer’s Disease
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
Otsuka Announces Phase 3 Topline Results of AVP-786 in the Treatment of Agitation Associated With Dementia Due to Alzheimer’s Disease
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
Otsuka Pharmaceutical Announces Positive Topline Results From Two Pivotal Phase 3 Trials of Centanafadine as a Treatment for Adolescents and Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
Otsuka and Lundbeck Published Study Results Showing Aripiprazole 2-Month, Ready-to-Use, Long-Acting Injectable is as Well-Tolerated, and Provides Similar Plasma Levels as Aripiprazole 1-Month for Treatment of Schizophrenia and Bipolar I Disorder
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
Otsuka and Lundbeck Announce FDA Acceptance and Priority Review of sNDA for Brexpiprazole for the Treatment of Agitation Associated With Alzheimer’s Dementia
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
Otsuka Pharmaceutical and Lundbeck Announce Positive Results Showing Reduced Agitation in Patients with Alzheimer’s Dementia Treated with Brexpiprazole
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
The McQuade Center for Strategic Research and Development and Mindset Pharma Collaborate to Develop Psychedelic Medicines
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
Otsuka and Lundbeck Announce FDA Acceptance of Supplemental New Drug Application; Receive Priority Review for Treatment of Schizophrenia in Adolescents
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
The McQuade Center for Strategic Research and Development Launches the Otsuka Digital Pioneer Initiative
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
The McQuade Center for Strategic Research and Development Enters Agreement with Sentinel Oncology to Develop Breakthrough Treatment for Fragile X Syndrome
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
Otsuka and Lundbeck Announce Decision to Continue Phase III Clinical Trial Evaluating Brexpiprazole for Treatment of Agitation in Patients With Alzheimer's-type Dementia
From Otsuka Pharmaceutical Co., Ltd.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.